BACKGROUND: the Radiation therapy oncology Group 98-11 clinical trial demonstrated the superiority of standard 5-fluorouracil/mitomycin-C over 5-fluorouracil/cisplatin in combination with radiation in the treatment of anal squamous cell cancer. tumor size (>5 cm) and lymph node metastases are associated with disease progression. there may be key molecular differences (eg, Dna methylation changes) in tumors at high risk for progression. OBJECTIVE: the objectives of this study were to determine whether there are differences in Dna methylation at individual CpG sites and within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared with those that are less advanced. DESIGN: this was a case-case study among 121 patients defined as high risk (tumor size >5 cm and/or nodal involvement; n = 59) or low risk (≤5 cm, node negative; n = 62) within the mitomycin-C arm of the Radiation therapy oncology Group 98-11 trial. Dna methylation was measured using the illumina humanmethylation450 array. SETTINGS: the study was conducted in a tertiary care cancer center in collaboration with a national clinical trials cooperative group. PATIENTS: the patients consisted of 74 women and 47 men with a median age of 54 years (range, 25-79 years).
a nal cancer accounts for 4% of all lower gastrointestinal tract malignancies in the united states, 1 and the incidence of anal cancer continues to rise by 2.6% per year. 2 in fact, the incidence rates of anal cancer have increased significantly in the past 30 years, jumping 160% in men and 78% in women. 3, 4 the overall 5-year survival rate for anal cancer is 65.6%; however, this varies considerably by stage of diagnosis (80% for local disease, 60% for regional disease, and 31% for distant disease at diagnosis). 5 Radiation, 5-fluorouracil, and mitomycin-C have remained the components of standard combined modality therapy over the last several decades despite the completion of several clinical trials. [6] [7] [8] [9] of these, the Radiation therapy oncology Group (RtoG) 98-11 trial evaluated 2 chemoradiation regimens for the treatment of anal canal carcinoma (standard mitomycin-based regimen versus an experimental cisplatin-based regimen). this trial included 644 patients and reported a significantly better 5-year disease-free survival in the mitomycin-C arm versus the cisplatin arm (68% vs 58%; p = 0.006). 6, 7 although this treatment is effective, there are significant associated morbidities, and alternative dosing or novel targeted treatments are needed to reduce the morbidity and improve outcomes for some patients.
tumor size and nodal status are strong clinical prognostic factors for anal cancer. 10 Within RTOG 98-11, patients with more advanced cancer at diagnosis, for example, large tumors (>5 cm in diameter) and/or positive lymph nodes, had poorer disease-free survival outcomes than those with less advanced disease. 7 however, both early and locoregionally advanced tumors had heterogeneous outcomes. We hypothesized that there are underlying biological differences between larger-size and/or node-positive tumors that put tumors at high risk of progressing and not responding to treatment. these differences may explain some of the variability in patient outcomes given the same treatment.
one such biological alteration important to carcinogenesis is Dna methylation, an epigenetic modification. 11, 12 epigenetic alterations encompass changes in chromatin structure, histone modification, and Dna methylation and play an important role in gene expression. methylation of Dna occurs specifically at discrete sites termed "CpG dinucleotides," where a cytosine (C) precedes a guanine (G). these CpG sites or loci generally reside in clusters known as CpG islands and are often associated with gene promoter regions. 12 Dense Dna methylation in CpG islands can result in the epigenetic silencing of tumor suppressor genes and are important to the process of carcinogenesis. 13 epigenetic gene silencing has been demonstrated in human papilloma virus (hPV)-associated cervical cancer and commonly occurs in pathways that are important in carcinogenesis. 13, 14 for example, aberrant activity of the well-described oncogenic WNT/βcatenin pathway is prominent in numerous cancer types, and genes encoding several key regulators of this pathway, such as CDH1, APC, and WIF1, are frequently silenced via dense methylation of CpG islands in cervical cancer. [15] [16] [17] although likely important, the role of Dna methylation in the development of anal cancer remains very poorly studied. 18, 19 Zhang et al 18 provided the first evidence of aberrant methylation in anal cancer among 11 candidate genes compared with normal tissue. subsequently using an array-based assay analyzing >1500 CpG sites, we observed differences in Dna methylation patterns in 20 genes in the progression from normal anal mucosa, carcinoma in situ, to invasive anal carcinoma in a small set of cases. 19 to date, a broad high-throughput characterization of methylation events in advanced anal cancer is clearly lacking. the objectives of this study were to determine whether there are differences in Dna methylation at individual CpG sites and clusters within genes among locally advanced anal cancers, with large tumor size and/or nodal involvement, compared to those that are less advanced. Trial as reported, 6, 7 this us Gastrointestinal intergroup trial RtoG 98-11 evaluated combinations of external beam irradiation plus chemotherapy in a 2-arm, phase iii randomized trial comparing external beam irradiation plus concurrent 5-fluorouracil and mitomycin-C with induction 5-fluorouracil plus cisplatin followed by concurrent external beam irradiation plus 5-fluorouracil plus cisplatin. 6 Patients were excluded if their primary diagnosis was t1 or m1, severe comorbid conditions (including aiDs), or previous malignancy within the past 5 years. 6 Randomization was stratified by sex, clinical nodal status (positive or negative), and size of the primary tumor (2-5 cm or >5 cm). for anal cancer, clinical lymph node staging was conducted by physical examination and radiologic imaging. all of the patients enrolled in RtoG 98-11 signed an institutional review board-approved informed consent form. the use of de-identified tissues was approved by the university of south florida institutional Review Board. this study includes patients from the mitomycin-C arm of RtoG 98-11 who had archived tumor tissue available (n = 186).
MATERIAL AND METHODS

RTOG 98-11 Tissue and DNA Extraction
archived, formalin-fixed, paraffin-embedded tumors were macrodissected, and genomic Dna was isolated using the Qiaamp Dna ffPe tissue kit (QiaGen, Valencia, Ca). Dna quality was evaluated using the quantitative polymerase chain reaction illumina ffPe QC kit (illumina, san Diego, Ca) in triplicate. samples with sufficient Dna (≥250 ng) that met criteria for inclusion in the QC assay (illumina) were included.
Bisulfite Modification and Infinium Methylation Analysis
Dna methylation cannot be measured directly and requires treatment with sodium bisulfite, which converts all unmethylated cytosines to uracil, whereas methylated cytosines are not altered. thus, genomic Dna is first sodium bisulfite modified using the eZ Dna methylation kit (Zymo Research, orange, Ca). Bisulfite-modified Dna was prepared using the infinium hD ffPe Dna Restore kit (illumina). methylation was interrogated using the Infinium HumanMethylation450K BeadChip, following the manufacturer's specifications throughout the wholegenome amplification, fragmentation, hybridization, base extension, counterstaining, and scanning. a tecan liquid handling robot with the te-flow apparatus (tecan Group ltd, männedorf, switzerland) was used for the single base extension and staining, and the chips were scanned on a single hiscansQ system (illumina). the infinium hu-manMethylation450K BeadChip incorporates both Infinium i (methylated and unmethylated beads per CpG locus) and infinium ii assays (1 bead type with the methylated state determined at the single base extension step after hybridization) to evaluate Dna methylation status at 485,512 CpG loci, which covers 99% of annotated genes and 96% of defined CpG islands. 20, 21 
Statistical Analysis
Patients were classified as low risk with a tumor diameter of ≤5 cm and node negativity and advanced high risk with a tumor diameter of >5 cm and/or node positivity. Patients were also grouped individually by tumor size (≤5 cm vs >5 cm) or nodal status (negative vs positive). Differences in patient characteristics were determined by χ 2 , fisher exact test, or t test. overall survival was defined as the time from randomization to death attributed to any cause. Disease-free survival was defined as the time from randomization to local, regional, or distant failure; second primary tumor; or death attributed to any cause. 6 Differences in survival by clinical risk group were estimated univariately with the Kaplan-Meier method, and the clinical risk groups were compared using the log-rank test.
methylated CpG loci were defined on the infinium array as a β-value, which was calculated for the 485,512 CpG loci from unmethylated (u) and methylated (m) signals [m/(u+m+100)] and assigned a range between 0 and 1 (unmethylated to 100% methylated). β Values with a corresponding detection p > 0.05 were set as missing. methylation data were preprocessed using the R statistical software package and Bioconductor packages methylumi and wateRmelon. 22 β Values were normalized using the normalizeViaControls function in the methylumi package. Chip-wide controls and multidimensional scaling plots were used to visualize data quality. β Values were analyzed as continuous variables. to quantitate differential methylation between high-and low-risk groups, we calculated the following: Δβ = β value high -β value low . a threshold of Δβ > 0.1 was required to identify potentially meaningful biological changes in methylation. Differential methylation between groups was analyzed using the Mann-Whitney test and Student t test at level of significance of p < 0.001. Differential methylation across regions of Dna required 5 or more CpG loci that were significantly different per annotated gene at a p < 0.05 by the Mann-Whitney or t test. statistical analysis was performed using the R statistical software and matlaB packages.
RESULTS
Patient Characteristics
We identified 186 patients from RTOG 98-11 randomized to the mitomycin-C arm with archived tumor tissue who were eligible for this study. a total of 121 cases had sufficient Dna for methylation analysis. there were no differences in tumor characteristics and outcomes between patients eligible for the methylation analysis compared with those in the mitomycin-C arm who were not included; therefore, the sample of 121 patients with anal cancer was representative of patients randomly assigned to the mitomycin-C arm of RtoG 98-11 (data not shown). the median age of the 121 patients was 54 years (range, 25-79 years; table 1). a majority of the patients were women (61%), white (87%), and highly functional (95% had Karnofsky performance status ≥80). sixty-two patients (51%) were classified as low risk and 59 (49%) as high risk. there were 88 (73%) and 33 patients (27%) with tumor sizes of ≤5 cm and >5 cm. nodal status was determined as node negative (n0) in 85 patients (70%) and node positive in 36 patients (30%). there were no statistically significant differences in the distribution of sex or age across clinical risk groups (table 1) .
Risk Groups Associated With Patient Outcomes
the classification of risk groups as low and high risk was confirmed by examining the relationship between clinical risk group and outcome ( fig. 1 ). the 5-year disease-free survival rates were 89% for the low-risk group and 49% for the high-risk group (p < 0.0001; fig. 1a ). the 5-year overall survival rates were 92% versus 64% for the lowand high-risk groups (p = 0.0003; fig. 1B ). similar differences in survival were observed when considering tumor size or nodal status individually (data not shown). these data confirm that, within the 121 cases, the risk groups were accurately classified and are representative of the entire mitomycin-C arm of RtoG 98-11.
Differentially Methylated CpG Sites by Risk Group
at p < 0.001, 16 CpG loci were differentially methylated between the low-and high-risk groups (table 2) . of these, 14 loci had increased methylation in high-risk tumors. these 16 CpG sites were located in 7 defined genes and 1 uncharacterized genomic region (see table 2 and supplemental Digital Content 1, http://links.lww.com/DCR/a144, for gene details). the individual contribution of tumor size and nodal status on methylation differences was also examined. a total of 68 CpG loci from 59 genes were differentially methylated in large tumors (table 3) . there were 61 sites with increased methylation levels within large tumors and 7 sites with decreased methylation. When considering nodal status, 8 CpG loci from 6 unique genomic regions were differentially methylated (5 with increased and 3 with decreased methylation) in tumors with nodal involvement (data not shown). there was no overlap in individual differentially methylated CpG sites between tumor size and nodal status. only 2 genes (3.5%) identified in the tumor size analysis were also significantly different by clinical risk group (tables 2 and 3), and 2 genes (33%) from the nodal analysis overlapped with risk group findings (data not shown).
Differential Methylation Within Genomic Regions
an individual methylated CpG site itself can serve as a detectable biomarker regardless of downstream impact on gene expression. however, prognostic biomarkers with functional biological relevance are of great interest. Given that functionally significant methylation is often associated with methylation across clusters of CpG sites, we next examined whether there were methylation differences in clusters of CpG sites within genomic regions between the high-and low-risk groups. at p < 0.05, we identified 6 genes with clusters of CpG sites differentially methylated in high-risk tumors (table 4) . figure 2 plots a 361 base pair region of the genome encoding the paraoxonase-3 (PON3) gene that includes 13 Testing was not applicable for tumor size and N stage, because those variables define the risk groups, similar to T stage, which is highly associated with tumor size by American Joint Committee on Cancer 1997 version definition.
CpG sites examined within a CpG island. Box plots represent the median and interquartile range (25 th and 75 th percentiles) of methylation levels in high-(blue boxes) and low-risk (red boxes) tumors. the median methylation for each of the 9 CpG sites (32% of CpG sites examined in the PON3 gene) was significantly lower in high-risk tumors than in low-risk tumors. figure 3 plots an ≈2-kb region of the sal-like 3 gene (SALL3) that includes 10 CpG sites within a CpG island. overall, 8 of 27 total sites examined had significantly higher methylation in the high-risk tumors. the genomic region with the most differentially methylated sites (loC728392) 
DISCUSSION
this study investigated whether Dna methylation differed between locally advanced (high-risk) or locoregionally confined (low-risk) anal cancers. to address this question, we conducted the first genome-wide investigation of Dna methylation in anal cancer using a well-annotated set of tumors archived within the RTOG 98-11 trial. We identified individual CpG sites and clusters of CpG sites that were differentially methylated in locally advanced tumors. furthermore, we identified a large number of CpG sites with differential methylation in larger (>5 cm) tumors, regardless of nodal status. these differentially methylated regions provide clues for future studies that can examine whether this dense Dna methylation leads to transcriptional silencing of genes within large or advanced tumors. although the biological impact of methylation at an individual CpG site is unknown, the differentially methylated or unmethylated CpG sites identified in advanced or large tumors may be developed as clinically applicable biomarkers. the findings of this study are in line with the growing appreciation that aberrant epigenetic events are critical in the process of cancer growth and progression. for example, differential methylation patterns have been reported in the progression of several malignancies, including prostate, 93, 94 bladder, 95, 96 renal cell, 47 esophageal, 97 hPV-positive and hPV-negative head and neck, 98, 99 and cervical cancers. 100, 101 in general, these articles reported that increased Dna methylation within CpG islands was associated with increasing tumor aggressiveness, 94, 101 and some epigenetic events seem to be early markers of progression. 100 in cervical cancer, methylation of RASSF2 was associated with increased tumor vascular invasion and shorter survival time, independent of tumor stage. 100 such differences in methylation provide biological insight into the mechanisms of carcinogenesis.
Dna methylation differences were observed in locally advanced anal cancers compared with early, less advanced tumors. tumor suppressor genes are often targets of Dna methylation-mediated inactivation, which, in turn, contributes to cancer progression. a loss of methylation can also be associated with re-expression of suppressed oncogenic elements, which can then also drive neoplastic growth. We identified 2 tumor suppressor genes with differentially methylated individual CpG sites or clusters of methylated sites in locally advanced anal cancers. SALL3 has been reported to be methylated in hepatocellular cancer. 25 secreted frizzled-related protein 2 (SFRP2) has been reported to be frequently methylated in several cancers, including cervical, 34 hPV-positive and -negative head and neck, 27 and prostate 28 (see table 2 and supplemental Digital Content 1). PON3 has been reported as an imprinted gene and observed here to have reduction methylation in advanced anal cancer. furthermore, there was a large number of differentially methylated CpG loci in large tumors, suggesting an accumulation of methylation events with progressive growth of a tumor. of these, 7 genes are tumor suppressor genes reported previously as methylated in other cancers (see table 3 and supplemental Digital Content 2, http://links.lww.com/DCR/a145). specifically, early B-cell factor 3 (EBF3) 37 and neuronal pentraxin i (NPTX1) 66, 67 have been reported as epigenetically altered in hPV-associated oropharyngeal and cervical cancers. increased methylation of EBF3 was highly correlated with hPV-16 infection in head and neck squamous cell carcinoma. 46 in addition, several genes found to be methylated in locally advanced or large anal tumors encode for proteins that interact with hPV oncogenes. for example, cyclindependent kinase 6 (CDK6) regulates the activity of tumor suppressor pRb, which is a target of hPV oncoprotein e7. in hPV-positive cervical cancer cell lines, the inactivation of CDK6 was critical for HPV-associated carcinogenesis. 38 notably, a large number of differentially methylated loci identified in this study occurred within genes that are not well characterized and may represent novel methylation targets. overall, this genome-wide methylation analysis identified several biologically relevant methylated genes that have been consistently found to be methylated in other cancers (including those associated with hPV). this epigenetic silencing may promote anal tumor growth and progression to advanced disease. a striking number of epigenetic alterations in CpG loci were identified within components of the WNT/βcatenin pathway 102 in anal tumors. the clustering of epigenetic alterations in the WNT/β-catenin pathway among larger or high-risk anal cancers is similar to what has been reported in hPV-associated cervical cancer. 17, 26, [103] [104] [105] the WNT signaling pathway appears to be a target of HPV, with both epigenetic 106 and gene expression-related alterations. 107 It is well established that WNT/β-catenin signaling is a critical component of cancer progression, and epigenetic alterations of both activators and inhibitors may promote aberrant cellular proliferation and carcinogenesis. These epigenetic changes within the WNT pathway warrant further exploration.
there were relatively few significant differentially methylated regions identified by nodal status or clinical risk groups. there are several possible explanations for the relatively few methylation differences by nodal status. first, epigenetic alterations may not play a role in nodal invasion, and, thus, our limited number of aberrantly methylated loci represents the only underlying changes. second, because of clinical lymph node staging (eg, physi-cal examination and/or radiologic imaging) in anal cancer, there is a possibility that clinically node-negative patients had occult, undetected micrometastatic disease. this would not only dilute the molecular comparison but result in minimizing differences in outcomes between nodepositive and node-negative patients. the observation of significantly better outcomes among node-negative patients provides evidence that misclassification of nodal status does not entirely explain these findings. finally, the cross-sectional design of this study limited our ability to identify the sequence of epigenetic alterations in anal cancer progression and to distinguish alterations that may be drivers or bystanders of neoplastic progression. future studies that determine the extent of epigenetic differences by nodal involvement and identify epigenomic signatures of patient outcomes are warranted.
this study represents the largest comprehensive, genome-wide molecular analysis (in this case, Dna methylation) of anal cancers, a rare malignancy with low tissue availability. the RtoG 98-11 specimen archive is one of the largest, fully annotated pretreatment anal squamous cell carcinoma tissue repositories available. Cases in this trial may not represent the general population with anal squamous cell carcinoma, especially high-risk populations such as those with hiV or immunocompromised patients. hiV status of cancer patients was unknown. this study is limited to patients in the mitomycin-C arm with available tumor tissue; however, this sample is representative of the mitomycin-C arm when comparing the distribution of demographic factors, pathologic factors, and outcomes ( fig. 2 ). Because of the limited availability of anal cancer tissues (especially fresh frozen), this study was unable to determine whether differences in methylation resulted in decreased mRna transcription. however, differential methylation events at specific loci may still represent potential biomarkers of hPV-associated carcinogenesis. furthermore, the characterization of clusters of differentially methylated CpG loci within CpG islands allows for the identification of biologically relevant targets for which expression is likely modulated by methylation and can be further investigated using in vitro and in vivo laboratory models. the molecular biology of anal cancers is not well characterized, and, based on this study alone, we cannot determine the most important epigenetic alterations among those identified. however, this study provides important candidate targets for future validation in other patient populations and using different methods, such as identifying loss of mRna or protein expression. using a genome-wide methylation analysis, this study has demonstrated that significant epigenetic alterations occur in the progression from early to later-stage locally advanced anal cancer. the overall differences in methylation may lend clues to understanding the molecular alterations that occur with the malignant progression of anal cancer. effective methylation-related biomarkers may ultimately guide modification of treatment for high-risk patients (≈50% of RtoG 98-11 patients), including radiation dose intensification, closer monitoring of dose completions and/or gaps in treatment, and even possibly the development of novel targeted, radiosensitizing agents. an emerging option for dose modification for patients with anal cancer is intensity-modulated radiation therapy, which has been associated with less acute toxicity, as reported in the RtoG-0529 trial, 108 and theoretically less potential for accelerated tumor repopulation because of treatment breaks. furthermore, these findings are also concordant with observations that hPV infection may be associated with extensive epigenetic modifications in the host genome that may impact tumor development and behavior. similar to other malignancies, these data suggest that the WNT pathway may play an important role in the progression of anal cancer. further exploration of the potential roles of methylation-related biomarkers, including the development of refined and validated epigenetic signatures of prognosis, will be useful in optimizing outcomes in patients with anal cancer. 
